Top and Current
Source: (remove) : Matthew Sykes
RSSJSONXMLCSV
Top and Current
Source: (remove) : Matthew Sykes
RSSJSONXMLCSV
Thu, August 1, 2024
Wed, July 31, 2024
Wed, July 17, 2024
Tue, July 9, 2024
Mon, May 13, 2024
Wed, May 1, 2024
Mon, April 15, 2024
Wed, April 10, 2024
Thu, January 18, 2024
Wed, January 17, 2024
Thu, December 7, 2023
Wed, November 1, 2023
Wed, October 25, 2023
Mon, October 23, 2023
Fri, October 20, 2023
Wed, August 9, 2023
Mon, July 24, 2023
Fri, July 21, 2023
Thu, July 13, 2023
Wed, May 24, 2023
Mon, May 15, 2023
Wed, April 19, 2023
Tue, April 18, 2023
Tue, March 7, 2023
Tue, February 28, 2023
Mon, February 6, 2023
Tue, November 22, 2022
Fri, November 4, 2022
Thu, October 13, 2022
Thu, August 18, 2022
Thu, July 14, 2022
Wed, April 13, 2022
Tue, June 15, 2021
Fri, June 4, 2021
Thu, June 3, 2021
Wed, December 2, 2020
Tue, June 11, 2019
Mon, September 17, 2018
Thu, February 20, 2014
Wed, October 24, 2012

Matthew Sykes Maintained (CDNA) at Strong Buy with Increased Target to $26 on, Aug 1st, 2024


Published on 2024-10-28 13:03:00 - WOPRAI, Matthew Sykes
  Print publication without navigation


Matthew Sykes of Goldman Sachs, Maintained "CareDx, Inc" (CDNA) at Strong Buy with Increased Target from $16 to $26 on, Aug 1st, 2024.

Matthew has made no other calls on CDNA in the last 4 months.



There are 3 other peers that have a rating on CDNA. Out of the 3 peers that are also analyzing CDNA, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Andrew Cooper of "Raymond James" Downgraded from Buy to Hold on, Monday, May 13th, 2024


These are the ratings of the 2 analyists that currently disagree with Matthew


  • Mason Carrico of "Stephens & Co." Maintained at Buy with Increased Target to $18 on, Monday, May 13th, 2024
  • Alexander Nowak of "Craig-Hallum" Upgraded from Hold to Strong Buy and Increased Target to $15 on, Wednesday, May 1st, 2024